Page last updated: 2024-12-07

benzoyltyrosine ethyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzoyltyrosine ethyl ester (BTEE) is a synthetic compound that has been studied for its potential therapeutic applications. BTEE is an analog of the naturally occurring amino acid tyrosine. The synthesis of BTEE typically involves the reaction of benzoyl chloride with tyrosine ethyl ester. BTEE has been shown to exhibit various biological activities, including anti-inflammatory, antioxidant, and neuroprotective effects. Research on BTEE is driven by its potential to treat various diseases, such as Alzheimer's disease, Parkinson's disease, and cancer. BTEE has also been investigated as a potential therapeutic agent for obesity and diabetes. The specific mechanism of action of BTEE is still under investigation, but it is believed to involve its interaction with specific receptors and enzymes in the body.'

ethyl N-benzoyl-L-tyrosinate : An L-tyrosine derivative that is the ethyl ester of N-benzoyltyrosine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID77033
CHEMBL ID33242
CHEBI ID91051
SCHEMBL ID1784498
MeSH IDM0049421

Synonyms (45)

Synonym
AC-19245
unii-j2p4c4rj59
ai3-28819
l-tyrosine, n-benzoyl-, ethyl ester
nsc 75895
j2p4c4rj59 ,
einecs 222-469-2
tyrosine, n-benzoyl-, ethyl ester, l-
ethyl benzoyltyrosinate
ethyl n-benzoyl-l-tyrosinate
n-benzoyl-l-tyrosine ethyl ester
3483-82-7
NCGC00166028-01
B-0850
B1140
btee
bz-tyr-oet
CHEMBL33242 ,
benzoyltyrosine ethyl ester
bdbm50100038
(s)-2-benzoylamino-3-(4-hydroxy-phenyl)-propionic acid ethyl ester
ethyl (2s)-2-benzamido-3-(4-hydroxyphenyl)propanoate
bz-tyr-oet; btee
A822427
benzoyl-tyr-oet
(s)-ethyl-2-benzoylamino-3-(4hydroxyphenyl)propionate
AM82325
benzoyl-l-tyrosine ethyl ester
phco-tyr-oet
CHEBI:91051
SCHEMBL1784498
ethyl 2-(benzoylamino)-3-(4-hydroxyphenyl)propanoate #
(s)-ethyl 2-benzamido-3-(4-hydroxyphenyl)propanoate
tyrosine, n-benzoyl-, ethyl ester
n-benzoyl-l-tyrosine ethyl ester, >=98.0% (nt)
Q27163040
n-benzoyltyrosine ethyl ester
MS-20626
AC8694
M03119
DTXSID60883977
AKOS016843037
n-benzoyl-l-tyrosineethylester
CS-W013955
HY-W013239
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
chromogenic compoundColourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
L-tyrosine derivativeA proteinogenic amino acid derivative resulting from reaction of L-tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-tyrosine by a heteroatom.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency1.82560.00798.23321,122.0200AID2546; AID2551
DNA polymerase kappa isoform 1Homo sapiens (human)Potency33.58750.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 3Homo sapiens (human)IC50 (µMol)0.38300.00060.60419.0000AID42347
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
positive regulation of endothelial cell proliferationC-C chemokine receptor type 3Homo sapiens (human)
chemotaxisC-C chemokine receptor type 3Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 3Homo sapiens (human)
cell adhesionC-C chemokine receptor type 3Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayC-C chemokine receptor type 3Homo sapiens (human)
positive regulation of angiogenesisC-C chemokine receptor type 3Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 3Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 3Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 3Homo sapiens (human)
immune responseC-C chemokine receptor type 3Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
chemokine receptor activityC-C chemokine receptor type 3Homo sapiens (human)
protein bindingC-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneC-C chemokine receptor type 3Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 3Homo sapiens (human)
cytoplasmC-C chemokine receptor type 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1149948Binding affinity to chymotrypsin (unknown origin) assessed as deacetylation1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Quantitative structure-activity relationship of chymotrypsin-ligand interactions.
AID42347Inhibitory activity against human eosinophil C-C chemokine receptor type 3 using [125I]- human eotaxin as the radioligand2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1.
AID1149944Binding affinity to chymotrypsin (unknown origin)1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Quantitative structure-activity relationship of chymotrypsin-ligand interactions.
AID1149943Binding affinity to chymotrypsin (unknown origin) assessed as hydrolysis1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Quantitative structure-activity relationship of chymotrypsin-ligand interactions.
AID1149947Binding affinity to chymotrypsin (unknown origin) assessed as acetylation at pH 71977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Quantitative structure-activity relationship of chymotrypsin-ligand interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (33.33)18.7374
1990's8 (44.44)18.2507
2000's3 (16.67)29.6817
2010's1 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.27 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]